Dacarbazine
- Generic Name
- Dacarbazine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
- Associated Therapies
- -
A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2013-08-19
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT00246012
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 101
- Registration Number
- NCT00110994
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 859
- Registration Number
- NCT00091572
Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma
- Conditions
- First Posted Date
- 2004-09-02
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Radiation Therapy Oncology Group
- Registration Number
- NCT00002791
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸Harbor Hospital Center, Baltimore, Maryland, United States
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall
- Conditions
- Interventions
- First Posted Date
- 2004-08-09
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 23
- Registration Number
- NCT00089544
- Locations
- 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
- Conditions
- First Posted Date
- 2004-05-12
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 500
- Registration Number
- NCT00002802
- Locations
- 🇩🇪
University of Cologne, Frechen, Germany
Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease
- Conditions
- Interventions
- First Posted Date
- 2004-04-15
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 99
- Registration Number
- NCT00004010
- Locations
- 🇺🇸
CCOP - Merit Care Hospital, Fargo, North Dakota, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
- Conditions
- First Posted Date
- 2004-03-23
- Last Posted Date
- 2008-07-25
- Lead Sponsor
- Vical
- Registration Number
- NCT00003647
- Locations
- 🇺🇸
Oncology and Hematology Associates, Westwood, Kansas, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease
- Conditions
- First Posted Date
- 2004-03-12
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 800
- Registration Number
- NCT00003421
- Locations
- 🇬🇧
Weston Park Hospital, Sheffield, England, United Kingdom
🇬🇧St. James's Hospital, Leeds, England, United Kingdom
Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease
- Conditions
- Interventions
- First Posted Date
- 2003-11-21
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 405
- Registration Number
- NCT00002561
- Locations
- 🇨🇦
Regional Health Authority B, Zone 2, Saint John, New Brunswick, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇬🇧Royal South Hants Hospital, Southampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.